Goldman Sachs analyst Corinne Jenkins raised the firm’s price target on Ideaya Biosciences to $48 from $47 and keeps a Buy rating on the shares. The firm noted that Ideaya announced interim results from an ongoing Phase 2 company-sponsored and investigator-sponsored study of darovasertib in neoadjuvant uveal melanoma. Overall, the firm believes this update reinforces the previously reported positive data from the investigator-sponsored trial and initial company-sponsored data.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Ideaya Biosciences price target lowered to $66 from $68 at Stifel
- Ideaya Type C meeting outcome ‘best case,’ says Oppenheimer
- Ideaya Biosciences announces interim darovasertib trial data
- Ideaya Biosciences announces Douglas Snyder as general counsel
- Ideaya Biosciences price target raised to $68 from $63 at Stifel